Literature DB >> 19235593

Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients.

Ogan Demir Abaan1, Pelin Kaya Mutlu, Yusuf Baran, Can Atalay, Ufuk Gunduz.   

Abstract

Multidrug resistance (MDR) is a serious handicap towards the effective treatment of breast cancer patients. One of the most prevalent MDR mechanisms is through the overexpression of genes coding the proteins called Multidrug Resistance-associated Proteins (MRPs). The aim of this study was to investigate the expression of MRP1 in tumor tissues from breast cancer patients. In this study, a semi-quantitative RT-PCR approach was utilized. Our results suggest that MRP1 overexpression can mediate MDR in patients. Pre-evaluation of the level of such MDR mediators before chemotherapy can increase the efficacy of the treatment.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19235593     DOI： 10.1080/07357900802173562

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  6 in total

1.  Phytochemical Inhibition of Multidrug Resistance Protein-1 as a Therapeutic Strategy for Hemangioendothelioma.

Authors:  Ayan Biswas; Emma C Clark; Chandan K Sen; Gayle M Gordillo
Journal:  Antioxid Redox Signal       Date:  2016-11-09       Impact factor: 8.401

2.  Altered characteristics of cancer stem/initiating cells in a breast cancer cell line treated with persistent 5-FU chemotherapy.

Authors:  Xinquan Lü; Qing Deng; Huixiang Li; Zhenhe Suo
Journal:  Exp Ther Med       Date:  2011-06-02       Impact factor: 2.447

3.  β-catenin knockdown enhances the effects of fluorouracil in the breast cancer cell line MDA-MB-468.

Authors:  Xinquan Lv; Xia Pang; Xiangdong Jin; Yimin Song; Huixiang Li
Journal:  Biomed Rep       Date:  2014-08-26

Review 4.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

Review 5.  Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Authors:  Gergely Szakács; Matthew D Hall; Michael M Gottesman; Ahcène Boumendjel; Remy Kachadourian; Brian J Day; Hélène Baubichon-Cortay; Attilio Di Pietro
Journal:  Chem Rev       Date:  2014-04-23       Impact factor: 60.622

6.  Identification of Novel Rare ABCC1 Transporter Mutations in Tumor Biopsies of Cancer Patients.

Authors:  Onat Kadioglu; Mohamed Saeed; Markus Munder; Andreas Spuller; Henry Johannes Greten; Thomas Efferth
Journal:  Cells       Date:  2020-01-26       Impact factor: 6.600
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.